Department of Neurobiology, Harvard Medical School

Fierce Names Dr. Dennis Wall, Founder of Cognoa, as One of its Fierce 50 Honorees of 2023

Retrieved on: 
Tuesday, October 3, 2023
Learning, Drug development, University, Health, PALO, Health care, Department of Neurobiology, Harvard Medical School, Intelligence, Medicine, Research, Doctor of Philosophy, Genetics, Computation, Fierce, Physician, Edison Theatre, Child, University of California, Berkeley, Spectrum, Genome, Growth, FDA, Family, Pharmaceutical industry, Nursing, Stanford University

PALO ALTO, Calif., Oct. 3, 2023 /PRNewswire/ -- Cognoa , the leading child health company, today announced that Fierce Healthcare and Fierce Life Sciences have named the company's Founder, Dr. Dennis Wall, as one of 2023's Fierce 50 honorees.

Key Points: 
  • PALO ALTO, Calif., Oct. 3, 2023 /PRNewswire/ -- Cognoa , the leading child health company, today announced that Fierce Healthcare and Fierce Life Sciences have named the company's Founder, Dr. Dennis Wall, as one of 2023's Fierce 50 honorees.
  • The Fierce 50 showcases 50 companies and individuals driving advancements in medicine, fostering innovation, and shaping the future of biopharma and healthcare.
  • The Fierce 50 is a constellation of the most brilliant visionaries and trailblazers, handpicked by the discerning editors of Fierce Biotech, Fierce Pharma and Fierce Healthcare.
  • The Fierce 50 honorees will be celebrated live at an evening gala at the Edison Ballroom in New York on December 5th.

Fierce Names Dr. Dennis Wall, Founder of Cognoa, as One of its Fierce 50 Honorees of 2023

Retrieved on: 
Tuesday, October 3, 2023
Learning, Drug development, University, Health, PALO, Health care, Department of Neurobiology, Harvard Medical School, Intelligence, Medicine, Research, Doctor of Philosophy, Genetics, Computation, Fierce, Physician, Edison Theatre, Child, University of California, Berkeley, Spectrum, Genome, Growth, FDA, Family, Pharmaceutical industry, Nursing, Stanford University

PALO ALTO, Calif., Oct. 3, 2023 /PRNewswire/ -- Cognoa , the leading child health company, today announced that Fierce Healthcare and Fierce Life Sciences have named the company's Founder, Dr. Dennis Wall, as one of 2023's Fierce 50 honorees.

Key Points: 
  • PALO ALTO, Calif., Oct. 3, 2023 /PRNewswire/ -- Cognoa , the leading child health company, today announced that Fierce Healthcare and Fierce Life Sciences have named the company's Founder, Dr. Dennis Wall, as one of 2023's Fierce 50 honorees.
  • The Fierce 50 showcases 50 companies and individuals driving advancements in medicine, fostering innovation, and shaping the future of biopharma and healthcare.
  • The Fierce 50 is a constellation of the most brilliant visionaries and trailblazers, handpicked by the discerning editors of Fierce Biotech, Fierce Pharma and Fierce Healthcare.
  • The Fierce 50 honorees will be celebrated live at an evening gala at the Edison Ballroom in New York on December 5th.

NYC Plastic Surgeon Dr. Brandon Elnekaveh Announces the Launch of his New Practice Website

Retrieved on: 
Tuesday, September 5, 2023
Rhinoplasty, Face, Yale Physician Associate Program, University, Elective surgery, American Society of Plastic Surgeons, Private practice, Breast augmentation, Multimedia, American Society for Aesthetic Plastic Surgery, Attending physician, Harvard Medical School, Suite, Injury, Patient, Department of Neurobiology, Harvard Medical School, Plastic, Aesthetic Plastic Surgery, Filler (linguistics), Cornell University, Northwell Health, Society, Female, Dentistry, Nursing

NEW YORK, Sept. 5, 2023 /PRNewswire-PRWeb/ -- Dr. Brandon Elnekaveh, a plastic surgeon based in New York City, is thrilled to announce the launch of his newly designed website, http://www.brandonplastics.com to provide comprehensive information about his premier practice. The user-friendly website details Dr. Elnekaveh's credentials, experience and patient reviews and provides an overview of the procedures he performs such as breast surgery, labiaplasty, body contouring, facial rejuvenation and non-surgical treatments. Patients can view before-and-after photos of real results and read in-depth information about what to expect. The website also highlights Dr. Elnekaveh's natural, nuanced approach to cosmetic surgery, as he truly understands that plastic surgery, cosmetic treatments and reconstructive procedures can be life-changing. From overcoming traumatic injuries that caused facial deformities to rejuvenating facial structures or contouring the body, Dr. Elnekaveh can provide life-changing results.

Key Points: 
  • Plastic Surgery is a premier source for aesthetic excellence in New York City and Long Island, NY.
  • NEW YORK, Sept. 5, 2023 /PRNewswire-PRWeb/ -- Dr. Brandon Elnekaveh, a plastic surgeon based in New York City , is thrilled to announce the launch of his newly designed website, http://www.brandonplastics.com to provide comprehensive information about his premier practice.
  • Dr. Brandon Elnekaveh is a plastic surgeon with offices in Manhattan and Long Island, NY.
  • In addition to his private practice, Dr. Elnekaveh serves as Attending Staff in the Department of Surgery/Plastic Surgery at multiple Northwell Health hospital locations.

Hitachi forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT

Retrieved on: 
Thursday, July 6, 2023
Antigen, Human, AMED, NEDO, Cone Health Women's Hospital, Teaching, New Energy and Industrial Technology Development Organization, Acute lymphoblastic leukemia, Cabinet Office, Massachusetts General Hospital, Research, Dopamine, Kyoto, Behavior, Lymphoma, MGB, Regenerative medicine, Harvard Medical School, Transplant, Department of Neurobiology, Harvard Medical School, Innovation Center station, Digital technology, Innovation system, Protein, Hospital, Parkinson's disease, MEXT, MD, Mass, FIRST, Immune system, Kyoto University, Cancer, Mass General Brigham, BWH, Ecosystem, Longevity, Rare, GCT, IPS, Gene, Medical research, United States Army Medical Research and Development Command, TSE, Disease, Pharmaceutical industry, Vaccine, Renewable energy, Science, Brigham

By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.

Key Points: 
  • By working with BWH researchers at the Mass General Brigham Gene and Cell Therapy Institute (GCTI), Hitachi will support the development of cellular models relating to various diseases.
  • Hitachi will also contribute to the advancement of GCT through cell culturing and the development of the culturing process required in GCT by bringing research achievements and business experience in the field of regenerative medicine and GCT.
  • Mass General Brigham is a world-leading eco-system for GCT research and clinical trials, with over 400 researchers working on ground-breaking gene and cell therapy research and treatment in pursuit of potential cures.
  • From an early stage, Mass General Brigham has been actively engaged in GCT research, creating GCTI in December 2022.

Research Describes Novel Laboratory Automation Platform for Preclinical Detection and Quantification of Behavior

Retrieved on: 
Wednesday, March 8, 2023
IASP, Department of Neurobiology, Harvard Medical School, Acquisition, Machine learning, Medicine, Boston Children's Hospital, BCH, Nervous system, FTIR, Analgesic, Behavior, International Association, Pain, International Association for the Study of Pain, Harvard Medical School, Hospital, Doctor of Philosophy, Safety, Medical imaging, DALLAS, Neuroscience, PAIN

BOSTON and DALLAS, March 8, 2023 /PRNewswire/ -- Researchers at Boston Children's Hospital and Harvard Medical School's Department of Neurobiology have developed a new approach to measure dynamic changes in behavior in an unbiased, observer-independent manner, according to a new study published in and featured on the cover of PAIN, the journal of the International Association for the Study of Pain (IASP). The investigators noted that this technology platform has the ability to characterize a broad range of physiological and pathological phenomena and can be applied to objectively and automatically characterize behaviors including such tactile hyperalgesia, sedation, and other neurological readouts.

Key Points: 
  • Results suggest new technology enables improved, high-volume characterization and quantification of in vivo behavior.
  • Principal Investigator, Clifford Woolf, Mb, BCh, PhD, Professor of Neurobiology at Harvard Medical School and Director of the F.M.
  • Kirby Neurobiology Center at Boston Children's Hospital
    This peer-reviewed study demonstrated the efficacy of a novel automated technology platform in recording freely behaving mice over time for continuous data acquisition.
  • In addition, researchers utilized a proprietary machine learning software for automatic extraction and quantification of behavior characters, allowing for objective, sensitive, and high-throughput measurement of the behavioral state of rodents.

BGV co-leads €10 million seed investment in neuroscience company FundaMental Pharma

Retrieved on: 
Thursday, November 17, 2022
Spinocerebellar ataxia, Department of Neurobiology, Harvard Medical School, Neurotoxicity, Patient, Neuroscience, Fundamental, Heidelberg University, Interdisciplinary Center Herzliya, Amyotrophic lateral sclerosis, VC, Neurodegeneration, BGV, ALS, Neuropharmacology, Therapy, Pharmaceutical industry, Management, Research

Amsterdam, The Netherlands, 17 November 2022 - BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma today announces that it has co-led, a 10 million Seed investment in FundaMental Pharma (FundaMental), a preclinical neuroscience company spun out of Heidelberg University with Thuja Capital.

Key Points: 
  • Amsterdam, The Netherlands, 17 November 2022 - BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma today announces that it has co-led, a 10 million Seed investment in FundaMental Pharma (FundaMental), a preclinical neuroscience company spun out of Heidelberg University with Thuja Capital.
  • BGV invested from its Fund IV and following the financing, Dr Keno Gutierrez, Partner at BGV, has been appointed Chair of the Board of FundaMental.
  • FundaMental is built on the pioneering research of Professor Hilmar Bading and Dr. Jing Yan.
  • In conjunction with the financing, FundaMental also announced several key senior management appointments and the Board of Directors of the company.

Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities

Retrieved on: 
Friday, August 12, 2022
Compugen, Department of Neurobiology, Harvard Medical School, Hebrew University of Jerusalem, Biomarker, CCL24, Internal medicine, Inflammation, Trial of the century, Forward-looking statement, Drug, Private Securities Litigation Reform Act, SEC, PRA Health Sciences, Parexel, Research, Communication, Department, Fibrosis, Patient, Review, Marketing, Therapy, Cirrhosis, Research and development, Doctor of Philosophy, Risk, Nature, Weizmann Institute of Science, Rhodes College, Primary sclerosing cholangitis, University, MBA, Physician, CMMB, Nasdaq, BS, Cros, Development, TEL, Pharmaceutical industry, Science, MD

TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development.

Key Points: 
  • Prior to Compugen, Dr. Vaknin served as Chief Technology Officer at Active P, where he led the development of orally available therapeutic peptides.
  • She has highly relevant experience leading clinical research programs in immuno-inflammation and orphan diseases.
  • I am delighted to welcome Ilan and Chris to the Chemomab senior team at this exciting time in our evolution."
  • Her career spans working in-house at pharmaceutical and biotechnology firms, as well as at major clinical research organizations (CROs).

2022 Bressler Prize Awarded to Dr. Sheila Nirenberg for Outstanding Accomplishments in Vision Science

Retrieved on: 
Tuesday, May 17, 2022
Department, PNAS, Risk, UCLA, Computational neuroscience, PLOS One, Rehabilitation, Cornell University, Doctor of Philosophy, Patient, Neuron, Goal, Retinal degeneration, Severe cognitive impairment, Nature, Clinical trial, Institute, Research, Nanette L. Laitman, Brain, Harvard University, Lighthouse Guild, Tech, Weill Cornell Medicine, Motion, Faculty, Department of Neurobiology, Harvard Medical School, Harvard Medical School, Optic nerve, Lighthouse, MD, CEO, MacArthur, GLOBE, Pharmaceutical industry, Management, Medical device, Neuroscience, Neurology

New York, May 17, 2022 (GLOBE NEWSWIRE) -- Lighthouse Guild , the leading not-for-profit vision and healthcare organization, announced today that Sheila Nirenberg, PhD, has been awarded the 2022 Bressler Prize for her outstanding advances in vision science, including deciphering the retinas neural code which is the key to restoring meaningful vision in people who are blind from retinal degeneration.

Key Points: 
  • New York, May 17, 2022 (GLOBE NEWSWIRE) -- Lighthouse Guild , the leading not-for-profit vision and healthcare organization, announced today that Sheila Nirenberg, PhD, has been awarded the 2022 Bressler Prize for her outstanding advances in vision science, including deciphering the retinas neural code which is the key to restoring meaningful vision in people who are blind from retinal degeneration.
  • Lighthouse Guild is committed to improving the lives of people with or at risk for vision loss.
  • While the number of patients is still small, the consistency is very promising, with no safety concerns so far, said Dr. Nirenberg.
  • As the 2022 Bressler Prize winner, Dr. Nirenberg will receive a prize of $25,000, and also lead Lighthouse Guilds Annual Bressler Vision Science Symposium in New York City this fall, where she will be joined by other innovators who will present their work.

Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors

Retrieved on: 
Thursday, May 5, 2022
Amgen, Baxter, Cancer, Board, Weizmann Institute of Science, Board of directors, Forward-looking statement, Pfizer, Department, Department of Neurobiology, Harvard Medical School, Nasdaq, Hebrew University of Jerusalem, U.S. Securities and Exchange Commission, Galapagos NV, GlaxoSmithKline, CpG, RNA, GLOBE, Therapure BioPharma Inc, Company, Biotechnology, Merck, Physics, Atmospheric Chemistry and Physics, Johnson & Johnson, Immunotherapy, Delaware Court, Acquisition, Delaware Court of Chancery, Duet, Industry, Therapy, Leadership, List of life sciences, STAT3, Sutro Biopharma, Shareholder, Harvard Medical School, BioLineRx, Bristol Myers Squibb, Sustainability Accounting Standards Board, Research, Fine chemical, Management, Takeda, Chemistry

Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, We are thrilled Dr. Hofstein is rejoining our Board.

Key Points: 
  • Joshua R. Lamstein, Chairman of Scopus BioPharma, stated, We are thrilled Dr. Hofstein is rejoining our Board.
  • Dr. Hofstein brings invaluable insights and unparalleled experience in building start-up biotechnology companies into industry leaders.
  • Over his career, Dr. Hofstein has been instrumental in the founding and/or leadership of over 60 biopharmaceutical and biotechnology companies.
  • Duet BioTherapeutics, a wholly-owned subsidiary of Scopus, was launched in September 2021 by Scopus BioPharma to integrate the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform.

Aptinyx Appoints Gilmore O’Neill, M.B., M.M.Sc., to Board of Directors

Retrieved on: 
Wednesday, October 20, 2021
Mental Health, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Biotechnology, Multiple sclerosis, Connective tissue disease, Neurology, Pharmacovigilance, Pain, University College Dublin, Chronic pain, Twitter, Private Securities Litigation Reform Act, Hospital, U.S. Securities and Exchange Commission, Medicine, Sarepta, Security (finance), Harvard Medical School, Degenerative disease, Government budget balance, Sarepta Therapeutics, Massachusetts, Annual report, Department, Central nervous system, Nervous system, Research, Leadership, Nasdaq, Massachusetts General Hospital, Harvard University, Biogen, Therapy, Lists of diseases, Neuromuscular disease, Patient, Bachelor of Medicine, Bachelor of Surgery, Brain, NMDA, Inc., Department of Neurobiology, Harvard Medical School, Science, Post-traumatic stress disorder, Movement disorders, Unity Biotechnology, APTX, Pharmaceutical industry, Management

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore ONeill, M.B., M.M.Sc., to the companys board of directors.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore ONeill, M.B., M.M.Sc., to the companys board of directors.
  • Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors, said Norbert Riedel, Ph.D., chief executive officer of Aptinyx.
  • I am confident that Gilmore will serve as an invaluable resource to Aptinyx as we continue to develop new therapeutic options for patients living with nervous system disorders.
  • He serves on the board of the Massachusetts Biotechnology Council and on the board of directors of Unity Biotechnology.